The lowering of the price target from $73 to $68 by Baird suggests a less optimistic view on Edwards Lifesciences' short-term performance. The Neutral rating indicates that the stock is expected to perform in line with the market, but the reduced price target may lead to a negative sentiment among investors, potentially impacting the stock price negatively in the short term.